Prediction of relapse after treatment of coccidioidomycosis. 1997

E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
Department of Internal Medicine, Naval Medical Center, San Diego, California, USA.

Relapse after apparently successful treatment of coccidioidomycosis has been a problem with both amphotericin B and the azoles. We conducted a retrospective cohort study of 34 patients who required therapy for coccidioidomycosis between 1973 and 1993; 10 relapsed and 25 (one patient received two courses of therapy) did not relapse during follow-up. The mean time to relapse after completion of therapy was 7.3 months (range, 1-21 months). All 34 patients responded clinically to therapy. A fourfold or greater decrease in titers of antibody, as determined by complement fixation (CF), during therapy was seen in seven (78%) of nine patients who relapsed and 17 (85%) of 20 patients who did not relapse (P = .956). There was no significant difference between relapsers and nonrelapsers in terms of the lowest CF titer during therapy, the CF titer at the end of therapy, or the peak CF titer. The risk of relapse was increased among those with a peak CF titer of > or = 1:256 (relative risk [RR] = 4.7; 95% confidence interval [CI] = 1.4-16.1), as compared with patients who did not mount such a high antibody response. Similarly, the risk of relapse was higher among those with serially negative coccidioidin skin tests (CSTs) than those with serially positive CSTs (RR = 4.8; 95% CI = 1.2-19.5). We conclude that clinical response, lowest CF titer, end-of-therapy CF titer, and decrease in the CF titer of at least fourfold are not predictive of relapse in patients with coccidioidomycosis. Negative serial coccidioidin skin tests and a peak CF antibody titer of > or = 1:256 are independently associated with increased risk of relapse.

UI MeSH Term Description Entries
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003047 Coccidioidomycosis Infection with a fungus of the genus COCCIDIOIDES, endemic to the SOUTHWESTERN UNITED STATES. It is sometimes called valley fever but should not be confused with RIFT VALLEY FEVER. Infection is caused by inhalation of airborne, fungal particles known as arthroconidia, a form of FUNGAL SPORES. A primary form is an acute, benign, self-limited respiratory infection. A secondary form is a virulent, severe, chronic, progressive granulomatous disease with systemic involvement. It can be detected by use of COCCIDIOIDIN. Coccidioides Infection,Coccidioides posadasii Infection,Coccidioidomycosis Infection,Coccidioides immitis Infection,San Joaquin Valley Fever,Valley Fever,Coccidioides Infections,Coccidioides immitis Infections,Coccidioides posadasii Infections,Coccidioidomycoses,Coccidioidomycosis Infections,Infection, Coccidioides,Infection, Coccidioides immitis,Infection, Coccidioides posadasii,Infection, Coccidioidomycosis,Valley Fevers
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
October 1969, The New England journal of medicine,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
May 2023, Journal of hand surgery global online,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
January 2009, The American journal on addictions,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
June 2019, The British journal of dermatology,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
January 1967, Zobozdravstveni vestnik,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
February 2003, Mycoses,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
February 1987, Transplantation proceedings,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
January 1988, Annals of the New York Academy of Sciences,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
January 1993, Current topics in medical mycology,
E C Oldfield, and W D Bone, and C R Martin, and G C Gray, and P Olson, and R F Schillaci
April 2017, The American journal of psychiatry,
Copied contents to your clipboard!